A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2011
11/22/2011	CA2489902C Thiazole derivatives as phosphodiesterase iv inhibitors
11/22/2011	CA2474106C A process for the extraction, purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent
11/22/2011	CA2471262C Pyrido(2,1-a)isoquinoline derivatives as dpp-iv inhibitors
11/22/2011	CA2352324C Derivatives of (-)-venlafaxine and methods of preparing and using the same
11/22/2011	CA2344989C Health food products
11/17/2011	WO2011143562A2 Il-1 binding proteins
11/17/2011	WO2011143366A1 Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
11/17/2011	WO2011143296A1 Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
11/17/2011	WO2011143208A1 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
11/17/2011	WO2011143129A1 Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
11/17/2011	WO2011142621A2 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan
11/17/2011	WO2011142478A1 Canagliflozin containing tablets
11/17/2011	WO2011142381A1 Benzo- or pyrido-imidazole derivative
11/17/2011	WO2011142359A1 Spiro compound and drug for activating adiponectin receptor
11/17/2011	WO2011141713A1 New bicyclic compounds as pi3-k and mtor inhibitors
11/17/2011	WO2011141419A1 Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
11/17/2011	WO2011140638A1 Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
11/17/2011	WO2011088272A9 Selective ampd2 inhibitors and methods for using the same
11/17/2011	WO2011083999A3 Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient
11/17/2011	WO2011075665A3 Beta-cell replication promoting compounds and methods of their use
11/17/2011	WO2011071916A3 Sr-bi as a predictor of human female infertility and responsiveness to treatment
11/17/2011	WO2011060104A3 Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
11/17/2011	WO2011057243A3 Administration of plant expressed oral tolerance agents
11/17/2011	WO2010137979A8 Combination of a leucine source and an omega- 3 unsaturated fatty acid source for use in the treatment of hypercalcaemia
11/17/2011	US20110281957 Enhanced bioactive formulations of resveratrol
11/17/2011	US20110281956 Use of thymus capitatus extract, satureja hortensis extract, or carvacrol for treating metabolic diseases
11/17/2011	US20110281955 Methods of treating obesity using antioxidant inflammation modulators
11/17/2011	US20110281954 Methods of synthesizing cinacalcet and salts thereof
11/17/2011	US20110281951 Compositions and methods for treating amyloidosis
11/17/2011	US20110281944 Method of a rhein compound for inhibiting pancreatic islet beta-cell dysfunction and preventing or treating a pancreatic islet beta-cell dysfunction related disorder
11/17/2011	US20110281939 Polynucleotide aptamer-based cross-linked materials and uses thereof
11/17/2011	US20110281923 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
11/17/2011	US20110281922 Amide thiazole derivative, preparation method and uses thereof
11/17/2011	US20110281913 Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics
11/17/2011	US20110281903 Bicyclic heterocyclic spiro compounds
11/17/2011	US20110281884 Fused derivatives as pi3kdelta inhibitors
11/17/2011	US20110281880 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
11/17/2011	US20110281878 INHIBITORS OF p38
11/17/2011	US20110281874 2-aminopyridine analogs as glucokinase activators
11/17/2011	US20110281873 Pyrimidine Compounds and Methods of Making and Using Same
11/17/2011	US20110281870 Novel substituted octahydrocyclopenta[c]pyrrol-4-amines as calcium channel blockers
11/17/2011	US20110281864 Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof
11/17/2011	US20110281859 Novel heterocyclic compounds as metap-2 inhibitors
11/17/2011	US20110281857 Pi3k/mtor kinase inhibitors
11/17/2011	US20110281854 Morpholine compounds
11/17/2011	US20110281852 Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
11/17/2011	US20110281848 Imidazole compounds having pharmaceutical activity towards the sigma receptor
11/17/2011	US20110281846 Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
11/17/2011	US20110281844 Non-imidazole alkylamines as histamine h3-receptor ligands and their therapeutic applications
11/17/2011	US20110281843 Substituted indazole derivatives active as kinase inhibitors
11/17/2011	US20110281841 Kinase Inhibitors
11/17/2011	US20110281840 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
11/17/2011	US20110281836 Silent desensitizers of neuronal NACHR and methods of use thereof
11/17/2011	US20110281835 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
11/17/2011	US20110281829 Novel composition
11/17/2011	US20110281818 High fructan cereal plants
11/17/2011	US20110281808 Composition and Method for Increasing Pre Workout Thermogenics
11/17/2011	US20110281798 Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs
11/17/2011	US20110281797 Site-specific monoconjugated insulinotropic glp-1 peptides
11/17/2011	US20110281796 Novel activin receptor and uses thereof
11/17/2011	US20110281795 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
11/17/2011	US20110281793 Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes
11/17/2011	US20110281792 Binding-site modified lectins and uses thereof
11/17/2011	US20110281791 Crystalline insulin-conjugates
11/17/2011	US20110281790 Insulin with a stable basal release profile
11/17/2011	US20110281292 Compositions and methods for identifying antigens which elicit an immune response
11/17/2011	US20110280974 Substances Having Body Mass Redistribution Properties
11/17/2011	US20110280971 Berry oils and products
11/17/2011	US20110280954 Compositions and methods for altering stool quality in an animal
11/17/2011	US20110280953 Compositions and methods for altering stool quality in an animal
11/17/2011	US20110280951 Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
11/17/2011	US20110280945 Novel method for the preparation of granulates of active constituents, and granulates as obtained
11/17/2011	US20110280941 Compositions of proton pump inhibitors and insulin secretagogues, and methods of their use to treat diabetes
11/17/2011	US20110280918 Composition comprising phospholipids in combination with ascorbic acid and cosmetic products comprising it
11/17/2011	US20110280908 Multimeric protein toxins to target cells having multiple identifying characteristics
11/17/2011	US20110280876 Mutated netrin - 4, fragments thereof and their use as medicines
11/17/2011	US20110280873 MCP1-Ig FUSION VARIANTS
11/17/2011	US20110280872 Methods for prevention and treatment of inflammation using anti-chemokine antibodies
11/17/2011	US20110280871 Methods for prevention and treatment of inflammation using anti-chemokine antibodies
11/17/2011	US20110280856 Treatment of alpha-galactosidase a deficiency
11/17/2011	US20110280855 Vitamin c compositions
11/17/2011	US20110280848 Composition comprising chicoric acid and/or derivatives thereof
11/17/2011	US20110280842 Methods of reprogramming cells
11/17/2011	US20110280841 Electroprocessing in Drug Delivery and Cell Encapsulation
11/17/2011	US20110280840 Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
11/17/2011	US20110280837 Bifidobacterium longum and hippocampal bdnf expression
11/17/2011	US20110280833 Peptides, derivatives and analogs thereof, and methods of using same
11/17/2011	US20110280832 Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
11/17/2011	US20110280830 Albumin Fusion Proteins
11/17/2011	US20110280800 Il-1 binding proteins
11/17/2011	DE102010023850A1 New nanoparticles comprising a core, a protective shell that covers the core, and heme- and hemin molecules covalently bonded to the protective shell or the core, useful as dietary supplement and for treating iron deficiency and cancer
11/17/2011	CA2835596A1 Benzo- or pyrido-imidazole derivative
11/17/2011	CA2833415A1 Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
11/17/2011	CA2800578A1 Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
11/17/2011	CA2799204A1 Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
11/17/2011	CA2799020A1 Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
11/16/2011	EP2386624A1 Complex microbial preparation for treating diabetes and preparative method and use thereof
11/16/2011	EP2386551A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
11/16/2011	EP2386550A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
11/16/2011	EP2386546A1 Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity

1 ... 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 ... 1298